Exhibit 99.2 West Pharmaceutical Services Reconciliation of ProForma Earnings Per Share to US GAAP basis Fully Diluted For the quarter ended June 30 For the year ended December 31 2004 forecast 2003 2004 forecast 2003 Low High Actual Low High Actual ------------------ ------ ---------------- ------- Earnings per share, Pro forma $0.61 $0.65 $0.66 $2.00 $2.10 $1.88 Cost associated with plant explosion/ medical device facility closure costs (0.14) (0.14) (0.18) (0.65) (0.52) 0.31 Equity affiliate gain - - - 0.04 0.04 - ----------------- ------- ------------------- ------- Earings per share, US GAAP $0.47 $0.51 $0.48 $1.39 $1.62 $2.19 The Company believes the comparisons of period-to-period results of its ongoing business operations are aided by excluding the insurance settlement, related uninsured costs and on-going additional production and legal costs associated with 2003 plant explosion in Kinston, N.C., and by excluding restructuring and impairment charges connected with the planned closure of its UK medical device facility. Pro-forma results also exclude a gain on the sale of real estate by the Company's affiliate in Mexico.
West Pharmaceutical Services (WST) 8-KWest Pharmaceutical Services to Explore Strategic Alternatives for Drug Delivery
Filed: 30 Jun 04, 12:00am